Screening and identification of five serum proteins as novel potential biomarkers for cured pulmonary tuberculosis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wang, Chong ^a   Wei, Li Liang ^b   Shi, Li Ying ^c   Pan, Zhi Fen ^d   Yu, Xiao Mei ^c   Li, Tian Yu ^a   Liu, Chang Ming ^a   Ping, Ze Peng ^a   Jiang, Ting Ting ^a   Chen, Zhong Liang ^a   Mao, Lian Gen ^a   Li, Zhong Jie ^a   Li, Ji Cheng ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b The Sixth Hospital of Shaoxing   (China)

^c ZHEJIANG HOSPITAL   (China)

^d Department of Stomatology The First Hospital of Jiaxing   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; ARHGDIB PROTEIN, HUMAN; BIOLOGICAL MARKER; COMPLEMENT COMPONENT C3; FICOLIN; LECTIN; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR 2; SERUM ALBUMIN; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; BLOOD; DISEASE FREE SURVIVAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MICROBIOLOGY; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RECEIVER OPERATING CHARACTERISTIC; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; APOLIPOPROTEINS A; BIOMARKERS; CHROMATOGRAPHY, LIQUID; COMPLEMENT C3; DISEASE-FREE SURVIVAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LECTINS; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; RHO GUANINE NUCLEOTIDE DISSOCIATION INHIBITOR BETA; ROC CURVE; SERUM ALBUMIN; TANDEM MASS SPECTROMETRY; TREATMENT OUTCOME; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84945313228     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15615     Document Type: Article

References (49)

1. Organization., W. H. Global Tuberculosis Report 2014. (2014) Available at: http://www.who.int/tb/publications/global-report/en/. (Accessed: 26th March 2015).
2. Organization., W. H. Treatment of tuberculosis-guidelines, 4th ed. (2009) Available at: http://whqlibdoc.who.int/publications/2010/9789241547833-eng.pdf?ua = 9789241547831. (Accessed: 26th November 2014).
3. Organization., W. H. Multidrug-resistant tuberculosis (MDR-TB) 2014 update. (2014) Available at: http://www.who.int/tb/challenges/mdr/en/. (Accessed: 6th April 2015).
4. Kargar, M. et al. Anti-tuberculosis drugs adverse reactions: a review of the Iranian literature. Expert Opin Drug Saf 13, 875-891 (2014).
5. Wilkinson, D., Bechan, S., Connolly, C., Standing, E. & Short, G. M. Should we take a history of prior treatment, and check sputum status at 2-3 months when treating patients for tuberculosis? Int J Tuberc Lung Dis 2, 52-55 (1998).
6. Kurbatova, E. V. et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med 3, 201-209 (2015).
7. Phillips, P. P., Fielding, K. & Nunn, A. J. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One 8, e63840 (2013).
8. Wallis, R. S. et al. Tuberculosis biomarkers discovery: developments, needs, and challenges. Lancet Infect Dis 13, 362-372 (2013).
9. Nahid, P. et al. Aptamer-based proteomic signature of intensive phase treatment response in pulmonary tuberculosis. Tuberculosis (Edinb) 94, 187-196 (2014).
10. Moraes, M. L. et al. Association of serum levels of iron, copper, and zinc, and inflammatory markers with bacteriological sputum conversion during tuberculosis treatment. Biol Trace Elem Res 160, 176-184 (2014).
11. Azzurri, A. et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 7, 1-8 (2005).
12. Technical Guidance Group of the Fifth National TB Epidemiological Survey & Survey., T.O.o.t.F.N.T.E. The fifth national tuberculosis epidemiological survey in 2010. Chin J Antituber 34, 485-508 (2012).
13. De Groote, M. A. et al. Elucidating novel serum biomarkers associated with pulmonary tuberculosis treatment. PLoS One 8, e61002 (2013).
14. Xu, D. D. et al. Discovery and identification of serum potential biomarkers for pulmonary tuberculosis using iTRAQ-coupled two-dimensional LC-MS/MS. Proteomics 14, 322-331 (2014).
15. Liu, J. et al. The discovery and identification of a candidate proteomic biomarker of active tuberculosis. BMC Infect Dis 13, 506 (2013).
16. Xu, X. J. & Tang, Y. M. Coronin-1a is a potential therapeutic target for activated T cell-related immune disorders. Apmis 123, 89-91 (2015).
17. Wu, Y. et al. Amyloid-beta precursor protein facilitates the regulator of calcineurin 1-mediated apoptosis by downregulating proteasome subunit alpha type-5 and proteasome subunit beta type-7. Neurobiol Aging 36, 169-177 (2015).
18. Naz, F., Anjum, F., Islam, A., Ahmad, F. & Hassan, M. I. Microtubule affinity-regulating kinase 4: structure, function, and regulation. Cell Biochem Biophys 67, 485-499 (2013).
19. Cegielski, J. P., Arab, L. & Cornoni-Huntley, J. Nutritional risk factors for tuberculosis among adults in the United States, 1971-1992. Am J Epidemiol 176, 409-422 (2012).
20. Kim, C. W. et al. Risk factors related with mortality in patient with pulmonary tuberculosis. Tuberc Respir Dis (Seoul) 73, 38-47 (2012).
21. Utermann, G. The mysteries of lipoprotein(a). Science 246, 904-910 (1989).
22. McLean, J. W. et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 330, 132-137 (1987).
23. Wang, C. et al. Serum complement C4b, fibronectin, and prolidase are associated with the pathological changes of pulmonary tuberculosis. BMC Infect Dis 14, 52 (2014).
24. Liu, J. et al. Screening and identification of potential biomarkers and establishment of the diagnostic serum proteomic model for the Traditional Chinese Medicine Syndromes of tuberculosis. J Ethnopharmacol 155, 1322-1331 (2014).
25. Albanna, A. S., Bachmann, K., White, D., Valiquette, C. & Menzies, D. Serum lipids as biomarkers for therapeutic monitoring of latent tuberculosis infection. Eur Respir J 42, 547-550 (2013).
26. Groysman, M., Hornstein, I., Alcover, A. & Katzav, S. Vav1 and Ly-GDI two regulators of Rho GTPases, function cooperatively as signal transducers in T cell antigen receptor-induced pathways. J Biol Chem 277, 50121-50130 (2002).
27. Wang, P. et al. GM3 signals regulating TNF-alpha expression are mediated by Rictor and Arhgdib in mouse melanoma B16 cells. Oncology 73, 430-438 (2007).
28. Mehta, P. et al. LyGDI, a novel SHIP-interacting protein, is a negative regulator of FcgammaR-mediated phagocytosis. PLoS One 6, e21175 (2011).
29. Yi, B. et al. Depletion of RhoGDI2 expression inhibits the ability of invasion and migration in pancreatic carcinoma. Int J Mol Med 34, 205-212 (2014).
30. Cho, H. J. et al. VEGF-C mediates RhoGDI2-induced gastric cancer cell metastasis and cisplatin resistance. Int J Cancer 135, 1553-1563 (2014).
31. Liu, S. et al. RhoGDI2 is expressed in human trophoblasts and involved in their migration by inhibiting the activation of RAC1. Biol Reprod 90, 88 (2014).
32. Li, L. J. & Ren, H. in Infectious Diseases 8th edn (eds Li, L. J. et al.) 214 (Beijing, People's Medical Publishing House, 2013).
33. Mashruwala, M. A. et al. A defect in the synthesis of Interferon-gamma by the T cells of Complement-C5 deficient mice leads to enhanced susceptibility for tuberculosis. Tuberculosis (Edinb) 91 Suppl 1, S82-89 (2011).
34. Senbagavalli, P. et al. Major histocompatibility complex class III (C2, C4, factor B) and C3 gene variants in patients with pulmonary tuberculosis. Hum Immunol 72, 173-178 (2011).
35. Araujo, Z. et al. Levels of complement C3 and C4 components in Amerindians living in an area with high prevalence of tuberculosis. Mem Inst Oswaldo Cruz 101, 359-364 (2006).
36. Runza, V. L., Schwaeble, W. & Mannel, D. N. Ficolins: novel pattern recognition molecules of the innate immune response. Immunobiology 213, 297-306 (2008).
37. Krarup, A., Thiel, S., Hansen, A., Fujita, T. & Jensenius, J. C. L-ficolin is a pattern recognition molecule specific for acetyl groups. J Biol Chem 279, 47513-47519 (2004).
38. Eisen, D. P. Mannose-binding lectin deficiency and respiratory tract infection. J Innate Immun 2, 114-122 (2010).
39. Faik, I. et al. Ficolin-2 levels and genetic polymorphisms of FCN2 in malaria. Hum Immunol 72, 74-79 (2011).
40. Liu, F. et al. Inadequate values from an interferon-gamma release assay for smear-negative tuberculosis in a high-burden setting. Int J Tuberc Lung Dis 18, 1496-1501 (2014).
41. Zhang, X. et al. Screening and identification of six serum microRNAs as novel potential combination biomarkers for pulmonary tuberculosis diagnosis. PLoS One 8, e81076 (2013).
42. Kim, P. S., Makhene, M., Sizemore, C. & Hafner, R. Viewpoint: Challenges and opportunities in tuberculosis research. J Infect Dis 205 Suppl 2, S347-352 (2012).
43. China, M.o.H.o.t.P.s.R.o. Diagnostic criteria for pulmonary tuberculosis. (2008) Available at: http://www.moh.gov.cn/publicfiles///business/cmsresources/zwgkzt/cmsrsdocument/doc3242.pdf. (Accessed: 15th November 2013).
44. Karp, N. A. et al. Addressing accuracy and precision issues in iTRAQ quantitation. Mol Cell Proteomics 9, 1885-1897 (2010).
45. Chen, G. et al. Urinary proteomics analysis for renal injury in hypertensive disorders of pregnancy with iTRAQ labeling and LC-MS/MS. Proteomics Clin Appl 5, 300-310 (2011).
46. Wang, Y. S. et al. Altered protein expression in serum from endometrial hyperplasia and carcinoma patients. J Hematol Oncol 4, 15 (2011).
47. Jin, G. Z. et al. iTRAQ-2DLC-ESI-MS/MS based identification of a new set of immunohistochemical biomarkers for classification of dysplastic nodules and small hepatocellular carcinoma. J Proteome Res 10, 3418-3428 (2011).
48. Xiao, Z. et al. Quantitative proteomic analysis of formalin-fixed and paraffin-embedded nasopharyngeal carcinoma using iTRAQ labeling, two-dimensional liquid chromatography, and tandem mass spectrometry. J Histochem Cytochem 58, 517-527 (2010).
49. Ye, H., Sun, L., Huang, X., Zhang, P. & Zhao, X. A proteomic approach for plasma biomarker discovery with 8-plex iTRAQ labeling and SCX-LC-MS/MS. Mol Cell Biochem 343, 91-99 (2010).